Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says

Trials into Possible Treatment for Agitation in Alzheimer’s Patients to Continue, Avanir Says
A potential oral treatment for agitation due to Alzheimer’s dementia, AVP-786,  will continue in advanced clinical testing after a fuller analysis of data from two completed Phase 3 trials, Avanir Pharmaceuticals said. Their results were conflicting, with one trial showing a significant easing of agitated behaviors in patients given a certain dose while the other did not. AVP 786 is designed to be a second-generation version of Avanir's Nuedexta, a two-drug combo approved to treat pseudobulbar affect — sudden and uncontrolled outbursts of laughing or crying without any obvious reason. Like Nuedexta, AVP-786 is a combination of dextromethorphan and quinidine, but it also contains deuterium, an isotope of hydrogen. Dextromethorphan is the component acting on the central nervous system (brain and spinal cord). It is also an over-the-counter cough suppressant that affects brain signals that trigger the cough reflex. Quinidine sulfate is a medicine that affects the way the heart beats and is used to treat abnormal heart rhythms. Deuterium, added to the dextromethorphan molecule, is thought to work with quinidine to help increase the availability of dextromethorphan in the body by slowing its metabolism. Although its exact mechanism of action is not fully known, researchers believe
Subscribe or to access all post and page content.